Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Issue 1 (March 2020)

• Record Type: Journal Article
• Authors: Poulos, Christine; Wakeford, Craig; Kinter, Elizabeth; Mange, Brennan; Schenk, Thomas; Jhaveri, Mehul
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 6:Issue 1(2020)
• Publication Date: 2020-03
• Subjects: Multiple sclerosis -- discrete choice -- patient -- physician -- preferences -- heterogeneity; Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/2055217320910778
• Languages: English
• ISSNs: 2055-2173

Abstract

Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treatment features and outcomes via a discrete-choice experiment. Method: Patients with self-reported multiple sclerosis and treating physicians participated in an online discrete-choice experiment. Patients, each considering a better or worse reference condition, and physicians, each considering two patient profiles, chose between hypothetical treatment profiles defined by seven attributes with varying levels: years until disability progression, number of relapses in the decade, mode of administration, dosing frequency, and risks of mild, moderate, and severe side effects. Latent class analysis was used to measure respondent preferences and identify potential subgroups with distinct preferences. Results: Distinct treatment preferences emerged among subgroups of patients ( n = 301) and physicians ( n = 308). Patients in class 1 (43% of sample) were most concerned about side effects; chief concerns of class 2 patients (57%) were delaying disability progression and avoiding severe side-effect risks. The most important attributes for physicians (by class) were delaying disability (class 1, 45%), avoiding severe side-effect risks and (class 2, 33%), and avoiding all side-effect risks (class 3, 22%). Conclusion: Patients and physicians have diverse preferences for multiple sclerosis treatments, reflecting heterogeneity in the disease course and available therapies and the need for shared decision making.